NOTCH1 and adenoid cystic carcinoma: In turn, 12 patients with adenoid cystic carcinoma and confirmed activating NOTCH1 mutations were targeted with monoclonal antibody, brontictuzumab, and the phase I study resulted in an objective response rate (ORR) of 17% [58].